Information

Home Information
  • Sep 18, 2024

Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug

On Wednesday, Applied Therapeutics, Inc. (NASDAQ:APLT) stock traded higher with a session volume of 31.75 million, compared to an average volume of 1.26 million, according to data from Benzinga Pro. The company announced an update on the ongoing New Drug Application (NDA) review of govorestat for Classic Galactosemia. Galactosemia is an inherited metabolic disorder that makes the body unable to process a sugar called galactose. Also Read: Why Is Rare Disease-Focused Applied Therapeutics Stock Tr

  • Sep 18, 2024

Bank of America Takes a Bullish Stance on These 2 Stocks

The Federal Reserve’s FOMC committee will meet today, and with the pace of inflation down to an annualized rate of 2.5%, the conventional wisdom expects the central bank to start cutting rates. The Fed has held its key funds rate at the 5.25% to 5.50% range since July of last year, in response to a generational spike in inflation. Most Fed watchers are predicting that the bank’s governors will approve a cut of 25 basis points, or 0.25%. While modest, that would mark the end of a 14-month tight m

  • Sep 18, 2024

Hedge Funds Shun the Brazil Trade Winning Fans in Wall Street

(Bloomberg) -- Some of Wall Street’s biggest banks are telling clients to place bullish bets on Brazil, calling an end to the malaise that has plagued local markets this year.Most Read from BloombergCalifornia’s Anti-Speeding Bill Can Be a Traffic Safety BreakthroughPipe Fire Near Houston Forces Residents to EvacuateTo Build a Happier City, Design for DensityLondon Mayor Plans to Pedestrianize Busy Oxford StreetNew York City’s Transit System Plans $65.4 Billion of Upgrades for Grand Central, Sub

  • Sep 18, 2024

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children. Recent published studies report up to 10.1 million U.S. children (ages 6-17) are estimated to suffer from pediatric OSA. Vivos’ DNA appliance is non-invasive, safe, comfortable, affordable, and highly effective. It is designed to reduce nighttime snoring and treat moderate to sever

Popular Post